Click on headlines below to download research

Balancing risk to optimise reward

Oxford BioMedica is a leader in lentivirus based gene technology and ongoing manufacturing deals (CTL019 with Novartis) underpin the valuation.

Harnessing the CAR-T

Over the past year, Oxford BioMedica’s outlook has been transformed. The near term is now geared to the emerging specialist production capabilities,…